NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the Company will be added to the Russell 3000 and Russell 2000 Indexes, effective after the U.S. market close on June 27, as part of the 2025 Russell indexes annual reconstitution. The Russell 3000 Index tracks the performance of the la ...

核心观点 - Galena Biopharma近期被上调至Zacks Rank 2（买入评级），反映其盈利预期的上升趋势，这通常对股价有积极影响 [1][4] - Zacks评级系统主要基于公司盈利预期的变化，而非主观因素，因此对短期股价走势有较强预测能力 [2][3][7] - 盈利预期的调整与股价短期波动高度相关，机构投资者利用盈利预期计算公司公允价值并推动交易 [5][6] Zacks评级系统 - Zacks评级系统通过跟踪卖方分析师对当前及未来年度每股收益（EPS）的共识预期（Zacks Consensus Estimate）来评估公司 [2] - 该系统将股票分为5个等级（从Zacks Rank 1到5），其中排名前20%的股票（如Galena Biopharma的2评级）通常表现出色 [8][11] - Zacks Rank 1股票自1988年以来年均回报率达25%，且系统覆盖的4000多只股票中仅5%获“强力买入”评级 [8][10] Galena Biopharma盈利预期 - 公司2025财年预计每股亏损0.28美元，与上年持平，但过去三个月Zacks共识预期上调33.3% [9] - 盈利预期的持续改善表明公司基本面可能向好，可能吸引投资者推高股价 [6][9] - 盈利预期修订趋势与短期股价波动的强相关性使Galena Biopharma成为潜在市场表现优异标的 [7][11] 盈利预期修订与股价关系 - 盈利潜力变化（通过盈利预期修订体现）与股价短期走势高度相关，因机构投资者据此调整估值模型并交易 [5] - Zacks评级系统通过捕捉盈利预期修订趋势，帮助投资者识别可能跑赢市场的股票 [7][11] - Galena Biopharma的评级上调反映其盈利前景改善，可能转化为买入压力及股价上涨 [4][6]

New appointments of Drs. Philip C. Amrein and Alex Kentsis Validate Lead Galinpepimut-S and SLS009 Programs as Company Approaches Key Inflection Points This YearNEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the appointment of two distinguished oncology leaders to its Scientific Advisor ...

- ASCO Presentation Supports SLS009 as a Potential Targeted Therapy for ASXL1 Mutated Colorectal Cancer – - 22,500 New Cases of Colorectal Cancer with High Microsatellite Instability per Year in the US: 55% ASXL1m Frequency – NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced preclinical eff ...

HIGHLIGHTS: Non-dilutive US$200 million funding package from Royal Gold, comprising a gold stream and NSR royalty, US$100 million of which is available immediatelyThe package provides the funding required to repay the Senior Debt facility and is expected to provide the necessary liquidity to fund all value accretive derisking activities through to a final investment decision Stream expected to represent a small percentage of the gold over the life of mine which, together with the modest NSR royalty, reinfor ...

Format: Fireside chat Date: Wednesday, May 21, 2025 Time: 8:20 a.m. ET Webcast Link: Click Here About SELLAS Life Sciences Group, Inc. NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Dr. Angelos Stergiou, President and Chief Executive Officer of SELLAS, will participate in a fireside ...

- First ASXL1 Pediatric Acute Myeloid Leukemia (AML) Patient Dosed at MD Anderson Cancer Center: Program Supported by Rare Pediatric Disease Designation (RPDD)NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the first pediatric AML patient has been dosed in the ongoing Phase 2 trial o ...

Exhibit 99.1 SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update – Announced Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 (tambiciclib) in Relapsed/Refractory (r/r) Acute Myeloid Leukemia (AML) Demonstrating 8.9 mOS in AML-MRC and 8.8 mOS in All r/r to Venetoclax-Based Regimens Patients– NEW YORK, NY May 13, 2025 -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical ...

– Announced Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 (tambiciclib) in Relapsed/Refractory (r/r) Acute Myeloid Leukemia (AML) Demonstrating 8.9 mOS in AML-MRC and 8.8 mOS in All r/r to Venetoclax-Based Regimens Patients – – SLS009 Shows Promising Efficacy in Pediatric Acute Lymphoblastic Leukemia (ALL) Xenograft Models – – Final Analysis of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in AML Anticipated in 2025 – – $28.4 million in Cash and Cash Equivalents as of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________ FORM 10-Q ________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-33958 7 Times Square, Suite 2503, New York, NY 10036 (646) 200-5278 (Address, including zip code, and tele ...